{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T19:29:35Z","timestamp":1691782175349},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00508-010-1515-x","type":"journal-article","created":{"date-parts":[[2011,1,20]],"date-time":"2011-01-20T07:28:45Z","timestamp":1295508525000},"page":"45-52","source":"Crossref","is-referenced-by-count":8,"title":["Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients \u2013 Results of the Austrian cohort of the ECHO study"],"prefix":"10.1007","volume":"123","author":[{"given":"Emanuel","family":"Zitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander R.","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Eigner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Kodras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Kovarik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Graf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"P\u00e9tavy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Watschinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,21]]},"reference":[{"key":"1515_CR1","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","volume":"73","author":"E Slatopolsky","year":"1999","unstructured":"Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999;73:S14\u20139","journal-title":"Kidney Int Suppl"},{"key":"1515_CR2","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","volume":"342","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478\u201383","journal-title":"N Engl J Med"},{"key":"1515_CR3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0735-1097(01)01781-8","volume":"39","author":"P Raggi","year":"2002","unstructured":"Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695\u2013701","journal-title":"J Am Coll Cardiol"},{"key":"1515_CR4","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/ndt\/13.8.2037","volume":"13","author":"S Ribeiro","year":"1998","unstructured":"Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, et al. Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998;13:2037\u201340","journal-title":"Nephrol Dial Transplant"},{"key":"1515_CR5","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208\u201318","journal-title":"J Am Soc Nephrol"},{"key":"1515_CR6","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/ndt\/gfm849","volume":"23","author":"ML Melamed","year":"2008","unstructured":"Melamed ML, Eustace JA, Plantinga LC, Jaar BG, Fink NE, Parekh RS, et al. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant 2008;23:1650\u20138","journal-title":"Nephrol Dial Transplant"},{"key":"1515_CR7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","volume":"52","author":"F Tentori","year":"2008","unstructured":"Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519\u201330","journal-title":"Am J Kidney Dis"},{"key":"1515_CR8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/ki.1990.187","volume":"38","author":"H Malluche","year":"1990","unstructured":"Malluche H, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990;38:193\u2013211","journal-title":"Kidney Int"},{"key":"1515_CR9","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945\u201353","journal-title":"Kidney Int"},{"key":"1515_CR10","first-page":"S1","volume":"42","author":"Anonymous","year":"2003","unstructured":"Anonymous. K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1\u2013201","journal-title":"Am J Kidney Dis"},{"key":"1515_CR11","first-page":"S1","volume":"113","author":"Anonymous","year":"2009","unstructured":"Anonymous. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1\u2013130","journal-title":"Kidney Int Suppl"},{"key":"1515_CR12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0272-6386(04)01103-5","volume":"44","author":"EW Young","year":"2004","unstructured":"Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:34\u20138","journal-title":"Am J Kidney Dis"},{"key":"1515_CR13","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2215\/CJN.01060308","volume":"3","author":"MD Danese","year":"2008","unstructured":"Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1423\u20139","journal-title":"Clin J Am Soc Nephrol"},{"key":"1515_CR14","unstructured":"Kramar R,Oberbauer R. Austrian Dialysis and Transplantation Registry (OEDTR), Annual Report 2008. Austrian Society of Nephrology; 2008"},{"key":"1515_CR15","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","volume":"31","author":"GA Block","year":"1998","unstructured":"Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium\u00d7phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607\u201317","journal-title":"Am J Kidney Dis"},{"key":"1515_CR16","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0272-6386(00)70064-3","volume":"35","author":"GA Block","year":"2000","unstructured":"Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000;35:1226\u201337","journal-title":"Am J Kidney Dis"},{"key":"1515_CR17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000073945","volume":"23","author":"SM Moe","year":"2003","unstructured":"Moe SM, Drueke TB Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 2003;23:369\u201379","journal-title":"Am J Nephrol"},{"key":"1515_CR18","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.95.7.4040","volume":"95","author":"EF Nemeth","year":"1998","unstructured":"Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998;95:4040\u20135","journal-title":"Proc Natl Acad Sci USA"},{"key":"1515_CR19","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516\u201325","journal-title":"N Engl J Med"},{"key":"1515_CR20","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","volume":"16","author":"JS Lindberg","year":"2005","unstructured":"Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800\u20137","journal-title":"J Am Soc Nephrol"},{"key":"1515_CR21","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/ndt\/gfp144","volume":"24","author":"P Urena","year":"2009","unstructured":"Urena P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N, et al. Cinacalcet and achievement of the NKF\/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice \u2013 the ECHO observational study. Nephrol Dial Transplant 2009;24:2852\u20139","journal-title":"Nephrol Dial Transplant"},{"key":"1515_CR22","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","volume":"68","author":"J Cunningham","year":"2005","unstructured":"Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793\u20131800","journal-title":"Kidney Int"},{"key":"1515_CR23","doi-asserted-by":"crossref","first-page":"898","DOI":"10.2215\/CJN.04381206","volume":"2","author":"GM Chertow","year":"2007","unstructured":"Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007;2:898\u2013905","journal-title":"Clin J Am Soc Nephrol"},{"key":"1515_CR24","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1172\/JCI117890","volume":"95","author":"A Arnold","year":"1995","unstructured":"Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Drueke TB. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995;95:2047\u201353","journal-title":"J Clin Invest"},{"key":"1515_CR25","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1681\/ASN.V1161141","volume":"11","author":"TB Drueke","year":"2000","unstructured":"Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000;11:1141\u201352","journal-title":"J Am Soc Nephrol"},{"key":"1515_CR26","first-page":"4003","volume":"117","author":"IZ Ben-Dov","year":"2007","unstructured":"Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007;117:4003\u20138","journal-title":"J Clin Invest"},{"key":"1515_CR27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/ki.2009.414","volume":"77","author":"H Komaba","year":"2010","unstructured":"Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010;77:232\u20138","journal-title":"Kidney Int"},{"key":"1515_CR28","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/ndt\/gfp743","volume":"25","author":"I Ohkido","year":"2010","unstructured":"Ohkido I, Yokoyama K, Imura A, Utsunomiya Y, Hosoya T, Nabeshima Y. Persistent alpha-Klotho (a-Kl) expression in theparathyroid glands of patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2010;25:1007\u20138","journal-title":"Nephrol Dial Transplant"},{"key":"1515_CR29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/(SICI)1098-2388(199703\/04)13:2<78::AID-SSU3>3.0.CO;2-Z","volume":"13","author":"Y Tominaga","year":"1997","unstructured":"Tominaga Y, Tanaka Y, Sato K, Nagasaka T, Takagi H. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997;13:78\u201386","journal-title":"Semin Surg Oncol"},{"key":"1515_CR30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/ndt\/gfn717","volume":"24","author":"H Komaba","year":"2009","unstructured":"Komaba H, Fukagawa M. Regression of parathyroid hyperplasia by calcimimetics \u2013 fact or illusion? Nephrol Dial Transplant 2009;24:707\u20139","journal-title":"Nephrol Dial Transplant"},{"key":"1515_CR31","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1097\/01.ASN.0000141016.20133.33","volume":"15","author":"M Mizobuchi","year":"2004","unstructured":"Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K, et al. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 2004;15:2579\u201387","journal-title":"J Am Soc Nephrol"},{"key":"1515_CR32","doi-asserted-by":"crossref","first-page":"F1390","DOI":"10.1152\/ajprenal.00262.2006","volume":"292","author":"ME Rodriguez","year":"2007","unstructured":"Rodriguez ME, Almaden Y, Canadillas S, Canalejo A, Siendones E, Lopez I, et al. The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Renal Physiol 2007;292:F1390\u20135","journal-title":"Am J Physiol Renal Physiol"},{"key":"1515_CR33","doi-asserted-by":"crossref","unstructured":"Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2010;Dec 10 (Epub ahead of print)","DOI":"10.1093\/ndt\/gfq219"},{"key":"1515_CR34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/009841096161122","volume":"48","author":"EH Jeffery","year":"1996","unstructured":"Jeffery EH, Abreo K, Burgess E, Cannata J,Greger JL. Systemic aluminum toxicity: effects on bone, hematopoietic tissue, and kidney. J Toxicol Environ Health 1996;48:649\u201365","journal-title":"J Toxicol Environ Health"},{"key":"1515_CR35","first-page":"337","volume":"11","author":"SW King","year":"1981","unstructured":"King SW, Savory J, Wills MR. Aluminum toxicity in relation to kidney disorders. Ann Clin Lab Sci 1981;11:337\u201342","journal-title":"Ann Clin Lab Sci"},{"key":"1515_CR36","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/ndt\/gfn026","volume":"23","author":"GA Block","year":"2008","unstructured":"Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008;23:2311\u20138","journal-title":"Nephrol Dial Transplant"},{"key":"1515_CR37","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","volume":"13","author":"WG Goodman","year":"2002","unstructured":"Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002;13:1017\u201324","journal-title":"J Am Soc Nephrol"},{"key":"1515_CR38","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","volume":"63","author":"JS Lindberg","year":"2003","unstructured":"Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium \u03b9 phosphorus in secondary hyperparathyroidism. Kidney Int 2003;63:248\u201354","journal-title":"Kidney Int"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-010-1515-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-010-1515-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-010-1515-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T18:19:59Z","timestamp":1637173199000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-010-1515-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":38,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["1515"],"URL":"https:\/\/doi.org\/10.1007\/s00508-010-1515-x","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}